Pharmaceuticals & Biotechnology
Growth: Good revenue growth. With 50.8% growth over past three years, the company is going strong.
Technicals: Bullish SharesGuru indicator.
Smart Money: Smart money has been increasing their position in the stock.
Buy Backs: Company has bought back it's stock in the past which is a good thing.
Balance Sheet: Strong Balance Sheet.
Size: It is among the top 200 market size companies of india.
Profitability: Very strong Profitability. One year profit margin are 17%.
Momentum: Stock is suffering a negative price momentum. Stock is down -3.7% in last 30 days.
Valuation | |
|---|---|
| Market Cap | 1.03 LCr |
| Price/Earnings (Trailing) | 22.02 |
| Price/Sales (Trailing) | 2.97 |
| EV/EBITDA | 10.54 |
| Price/Free Cashflow | 54.7 |
| MarketCap/EBT | 13.42 |
| Enterprise Value | 1.03 LCr |
Fundamentals | |
|---|---|
| Revenue (TTM) | 34.79 kCr |
| Rev. Growth (Yr) | 12.4% |
| Earnings (TTM) | 5.74 kCr |
| Earnings Growth (Yr) | 1.3% |
Profitability | |
|---|---|
| Operating Margin | 22% |
| EBT Margin | 22% |
| Return on Equity | 16.93% |
| Return on Assets | 11.62% |
| Free Cashflow Yield | 1.83% |
Growth & Returns | |
|---|---|
| Price Change 1W | -0.60% |
| Price Change 1M | -3.7% |
| Price Change 6M | -1% |
| Price Change 1Y | 2.2% |
| 3Y Cumulative Return | 11.8% |
| 5Y Cumulative Return | 4.8% |
| 7Y Cumulative Return | 13.2% |
| 10Y Cumulative Return | 7.2% |
Cash Flow & Liquidity | |
|---|---|
| Cash Flow from Investing (TTM) | -5.1 kCr |
| Cash Flow from Operations (TTM) | 4.64 kCr |
| Cash Flow from Financing (TTM) | 1.19 kCr |
| Cash & Equivalents | 1.47 kCr |
| Free Cash Flow (TTM) | 1.89 kCr |
| Free Cash Flow/Share (TTM) | 22.67 |
Balance Sheet | |
|---|---|
| Total Assets | 49.43 kCr |
| Total Liabilities | 15.5 kCr |
| Shareholder Equity | 33.93 kCr |
| Current Assets | 25.02 kCr |
| Current Liabilities | 13.03 kCr |
| Net PPE | 7.3 kCr |
| Inventory | 7.11 kCr |
| Goodwill | 1.31 kCr |
Capital Structure & Leverage | |
|---|---|
| Debt Ratio | 0.08 |
| Debt/Equity | 0.12 |
| Interest Coverage | 24.12 |
| Interest/Cashflow Ops | 16.17 |
Dividend & Shareholder Returns | |
|---|---|
| Dividend/Share (TTM) | 8 |
| Dividend Yield | 0.65% |
| Shares Dilution (1Y) | 0.10% |
| Shares Dilution (3Y) | 0.30% |
Updated May 6, 2025
Dr. Reddy’s Laboratories is set to launch Beyfortus, a novel RSV drug for infants, expanding its immunization portfolio.
The drug Beyfortus, containing the monoclonal antibody nirsevimab, has been approved for use in multiple countries globally.
This collaboration with Sanofi marks a significant advancement in protecting children from the RSV disease burden in India.
Press Release / Media Release • 24 Nov 2025 Announcement under Regulation 30 of SEBI (LODR) Regulations, 2015 - Press Release |
Newspaper Publication • 18 Nov 2025 Copies of newspaper publication |
Analyst / Investor Meet • 18 Nov 2025 Intimation of Analyst meet |
Analyst / Investor Meet • 17 Nov 2025 Initmation of Analyst meet |
General • 14 Nov 2025 Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 |
Allotment of ESOP / ESPS • 13 Nov 2025 Allotment of Employee Stock Options |
General • 11 Nov 2025 Reply to clarification sought by BSE |
This information is AI-generated and may contain inaccuracies. Please verify from multiple sources.
Summary of Dr. Reddy's Lab's latest earnings call, featuring management's outlook on business performance, financial results, and analyst Q&A sessions that highlight key strategic initiatives and market challenges.
Last updated:
Last updated:
Analysis of Dr. Reddy's Lab's financial performance, highlighting revenue trends, growth patterns, and key metrics through quarterly analysis.
Last Updated: Sep 30, 2025
| Description | Share | Value |
|---|---|---|
| a) Global Generics | 86.6% | 7.8 kCr |
| b) Pharmaceutical Services and Active Ingredients | 13.4% | 1.2 kCr |
| Total | 9 kCr |
Understand Dr. Reddy's Lab ownership landscape with insights into key distribution patterns, offering investors a clear view of stakeholder dynamics.
| Shareholder Name | Holding % |
|---|---|
| GVP Family Trust | 11.51% |
| J P Morgan Chase Bank NA | 10.83% |
| LIFE INSURANCE CORPORATION OF INDIA P & GS FUND | 9.69% |
| VSD Family Trust | 9.06% |
| ICICI PRUDENTIAL VALUE DISCOVERY FUND | 4.34% |
| KALLAM SATISH REDDY HUF | 3.31% |
| NPS TRUST-A/C SBI PENSION FUND SCHEME TAX SAVER-TIER 2 | 2.49% |
| GUNUPATI VENKATESWARA PRASAD HUF | 1.52% |
| SATISH REDDY KALLAM | 1.21% |
| ANURADHA GUNUPATI | 0.01% |
| G V PRASAD | 0% |
| K SHRAVYA REDDY | 0% |
| K VISHAL REDDY | 0% |
| VSD Holdings & Advisory LLP | 0% |
| APS Trust | 0% |
| SHARATHCHANDRA REDDY GUNUPATI | 0% |
| GUNUPATI MALLIKA REDDY | 0% |
| DEEPTI REDDY KALLAM | 0% |
| G VANI SANJANA REDDY | 0% |
Distribution across major stakeholders
Distribution across major institutional holders
Detailed comparison of Dr. Reddy's Lab against industry peers, highlighting key financial metrics, valuation ratios, and performance indicators to provide competitive context within the sector.
Ticker | Name | Mkt Cap | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | Sun Pharmaceutical Industries | 4.26 LCr | 56.98 kCr | +4.60% | -1.20% | 40.75 | 7.48 | - | - |
| DIVISLAB | Divi's Lab | 1.7 LCr | 10.46 kCr | -2.80% | +4.50% | 68.51 | 16.27 | - | - |
| CIPLA | Cipla | 1.22 LCr | 29.39 kCr | -5.00% | +2.60% | 22.33 | 4.14 | - | - |
| LUPIN | Lupin | 93.28 kCr | 25.03 kCr | +5.80% | -3.10% | 21.56 | 3.73 | - | - |
| AUROPHARMA | Aurobindo Pharma | 70.16 kCr | 33.03 kCr | +11.30% | -2.70% | 20.5 | 2.12 | - | - |
Comprehensive comparison against sector averages
DRREDDY metrics compared to Pharmaceuticals
| Category | DRREDDY | Pharmaceuticals |
|---|---|---|
| PE | 21.84 | 35.11 |
| PS | 2.94 | 4.96 |
| Growth | 16.5 % | 9.8 % |
Dr. Reddy's Laboratories Ltd. is a prominent pharmaceutical company with its stock ticker known as DRREDDY. It boasts a substantial market capitalization of Rs. 100,022.4 Crores and is headquartered in Hyderabad, India.
The company operates globally through various segments:
Global Generics: This segment focuses on manufacturing and marketing both prescription and over-the-counter pharmaceutical products, including branded and generic finished dosages. It also has a presence in the biologics business.
Pharmaceutical Services and Active Ingredients (PSAI): Dr. Reddy's manufactures and markets active pharmaceutical ingredients (APIs) and intermediates that serve as crucial components for finished pharmaceutical products. This segment also provides contract research services and manufactures steroids according to customer specifications.
Others: This sector is dedicated to developing therapies in oncology and inflammation, engaging in R&D for differentiated formulations, and offering digital healthcare and IT-enabled business support services.
The company’s product offerings cover a wide range of therapeutic categories, including gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology.
Founded in 1984, Dr. Reddy's Lab has generated a trailing 12-month revenue of Rs. 32,071.7 Crores, demonstrating significant financial growth with a revenue increase of 50.6% over the past three years. The company is profitable, having achieved a profit of Rs. 5,448.3 Crores in the past four quarters.
Investors are rewarded with dividends, yielding 0.6% annually, with the last distribution being Rs. 8 per share. However, it is notable that the company has diluted its shareholders' stake by 0.3% in the past three years.
This is an informational page just to provide a quick 'first look' at the stock. You must do your own deeper research. Know your risk appetite. Consult a SEBI-registered financial advisor before making any investment decisions.
DRREDDY vs Pharmaceuticals (2021 - 2025)